Edmond DE Rothschild Holding S.A. Invests $129.79 Million in Illumina, Inc. $ILMN

Edmond DE Rothschild Holding S.A. bought a new stake in Illumina, Inc. (NASDAQ:ILMN) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 738,165 shares of the life sciences company’s stock, valued at approximately $129,792,000. Illumina accounts for 1.7% of Edmond DE Rothschild Holding S.A.’s portfolio, making the stock its 12th biggest position.

Several other institutional investors and hedge funds have also modified their holdings of ILMN. BlackRock Inc. bought a new position in Illumina during the second quarter worth about $3,374,423,000. WCM Investment Management LLC raised its stake in Illumina by 45.5% in the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in Illumina in the 2nd quarter valued at about $293,846,000. Invesco Ltd. boosted its holdings in Illumina by 97.0% in the 4th quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock valued at $360,426,000 after purchasing an additional 1,352,731 shares during the period. Finally, AQR Capital Management LLC grew its position in shares of Illumina by 30.3% during the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after purchasing an additional 1,028,099 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Keith A. Meister sold 457,858 shares of Illumina stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the transaction, the director owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. This trade represents a 16.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $200.00, for a total value of $123,000.00. Following the transaction, the insider directly owned 20,338 shares of the company’s stock, valued at $4,067,600. This trade represents a 2.94% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,415,351 shares of company stock valued at $255,966,311 in the last three months. Company insiders own 2.90% of the company’s stock.

Illumina Price Performance

ILMN stock opened at $205.00 on Thursday. The company’s 50-day moving average price is $185.90 and its two-hundred day moving average price is $151.49. The firm has a market cap of $30.95 billion, a P/E ratio of 38.25, a P/E/G ratio of 2.65 and a beta of 1.45. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $207.00.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the topic of several recent research reports. Royal Bank Of Canada raised their target price on shares of Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Evercore reissued an “outperform” rating on shares of Illumina in a research report on Monday, July 6th. Stifel Nicolaus raised their price objective on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Barclays raised their price objective on Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a research note on Friday, July 31st. Finally, Deutsche Bank Aktiengesellschaft downgraded Illumina to a “hold” rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $188.40.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.